Brain

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in...

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed...

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll...

PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company...

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin...

Catalyst MedTech Secures Exclusive U.S. Distribution of CareMiBrain™ PET System with NeuroQ4™, Showcasing a complete Neurologic PET Solution at SNMMI 2025

PITTSBURGH, June 20, 2025 /PRNewswire/ -- Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, has announced...

error: Content is protected !!